Cargando…

The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia

Background: Personal variations in genetic risk for schizophrenia relate to its phenotypic heterogeneity—both in disorder development and clinical manifestations. Abnormal glutamatergic neurotransmitter system functioning is integrated in the pathogenesis of schizophrenia. Methods: A sample of 805 R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poltavskaya, Evgeniya G., Kornetova, Elena G., Freidin, Maxim B., Pozhidaev, Ivan V., Paderina, Diana Z., Bocharova, Anna V., Semke, Arkadiy V., Bokhan, Nikolay A., Ivanova, Svetlana A., Fedorenko, Olga Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048659/ https://www.ncbi.nlm.nih.gov/pubmed/36980845 http://dx.doi.org/10.3390/genes14030575

Ejemplares similares

Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
por: Fedorenko, Olga Yu., et al.
Publicado: (2022)

Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2021)

Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
por: Boiko, Anastasiia S, et al.
Publicado: (2021)

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
por: Paderina, Diana Z., et al.
Publicado: (2022)

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
por: Pozhidaev, Ivan V., et al.
Publicado: (2020)

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
por: Pozhidaev, Ivan V, et al.
Publicado: (2020)

Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

PM515. The association between serotonin receptor gene polymorphisms and hyperprolactinemia in antipsychotic drug-treated schizophrenic patients
por: Ivanova, Svetlana, et al.
Publicado: (2016)

Genetic polymorphisms of PIP5K2A and course of schizophrenia
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2020)

Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
por: Poltavskaya, Evgeniya G., et al.
Publicado: (2021)

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
por: Osmanova, Diana Z., et al.
Publicado: (2019)

Association of rs11644461 GRIN2A with clinical phenotype of schizophrenia
por: Poltavskaya, E., et al.
Publicado: (2023)

Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2022)

Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
por: Fedorenko, Olga Yu., et al.
Publicado: (2020)

Association between 8 P‐glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug‐induced hyperprolactinaemia
por: Geers, Lisanne M., et al.
Publicado: (2020)

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
por: Boiko, Anastasiia S., et al.
Publicado: (2022)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
por: Boiko, Anastasiia S, et al.
Publicado: (2020)

Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
por: Boiko, Anastasiia S., et al.
Publicado: (2019)

Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
por: Mednova, Irina A., et al.
Publicado: (2022)

Drug-induced metabolic syndrome hasn’t associations with 5-HT receptor genes polymorphisms in patients with schizophrenia
por: Paderina, D., et al.
Publicado: (2021)

Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
por: Mednova, Irina A., et al.
Publicado: (2020)

Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study
por: Mednova, Irina A., et al.
Publicado: (2021)

Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
por: Ivanova, Svetlana A, et al.
Publicado: (2016)

Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
por: Kornetova, Elena G., et al.
Publicado: (2021)

Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
por: Kornetova, Elena G., et al.
Publicado: (2020)

Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
por: Boiko, A., et al.
Publicado: (2021)

Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia
por: Parshukova, Daria A., et al.
Publicado: (2020)

Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia
por: Ermakov, Evgeny A., et al.
Publicado: (2017)

Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
por: Fedorenko, Olga Yu, et al.
Publicado: (2015)

Serum Growth Factors in Schizophrenia Patients
por: Boiko, Anastasiia S., et al.
Publicado: (2023)

Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression
por: Ochi, Taichi, et al.
Publicado: (2019)

Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction
por: Smirnova, Liudmila P., et al.
Publicado: (2021)

DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia
por: Ermakov, Evgeny A., et al.
Publicado: (2015)

Association of PIP4K2A Polymorphisms with Alcohol Use Disorder
por: Fedorenko, Olga Yu., et al.
Publicado: (2021)

The difference in serum proteomes in schizophrenia and bipolar disorder
por: Smirnova, Liudmila, et al.
Publicado: (2019)

Building Predictive Models for Schizophrenia Diagnosis with Peripheral Inflammatory Biomarkers
por: Kozyrev, Evgeny A., et al.
Publicado: (2023)

Investigation of the role of polymorphic variants FTO gene in schizophrenia patients with metabolic syndrome
por: Pozhidaev, I., et al.
Publicado: (2021)

M210. GRIN2B METHYLATION IS RELATED TO PANSS EXCITED COMPONENT (PANSS-EC) IN SCHIZOPHRENIA
por: Fachim, Helene, et al.
Publicado: (2020)

Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design
por: Geers, Lisanne M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1jttthgvted3f3556f2uke5mrj